Azole-phenyl urea derivatives as ACAT inhibitors and their production
申请人:NIHON NOHYAKU CO., LTD.
公开号:EP0761658A1
公开(公告)日:1997-03-12
The present invention relates to azole-phenyl urea derivatives represented by the general formula (I):
[wherein each of R1, R2 and R3 is H, halogen, C1-8alkyl or the like, and A is a group represented by the formula (i) or (ii):
(wherein R4, R5, R6 and X are as defined in the specification.)] and a pharmacologically acceptable salt thereof, which have ACAT-inhibitory activity and are useful as a prophylactic and therapeutic agent for hypercholesterolemia, atherosclerosis and various diseases caused by them; a process for producing said derivative; and an ACAT inhibitor containing said derivative or salt as an active ingredient.
Twenty kinds of oxazole derivatives having various substituents at the C-2 and C-5 positions were synthesized and tested in vitro for inhibition of rabbit lens aldose reductase (Ia and Ib), the enzyme that initiates cataract formation in diabetes. Compounds possessing bulky groups at C-2 and C-5 of the oxazole skeleton were found to be potent inhibitors. Benzyl 5-phenyl-2-oxazolecarbamate (12) inhibited aldose reductases Ia and Ib by 50% at about 15μM. N-Phenyl-N'-(5-phenyl-2-oxazolyl) urea also exhibited inhibitory activity comparable to that of compound 12. The structure-inhibitory activity relationships are discussed.